Biosimilars Newco

Biosimilars Newco Limited is a UK-based biopharmaceutical company and a wholly owned subsidiary of Biocon Biologics, established to manage the global biosimilars portfolio acquired from Viatris in 2022. The company holds the intellectual property and commercialization rights for a robust range of high-quality biosimilar products, including Yesafili (aflibercept), Ogivri (trastuzumab), and Abevmy (bevacizumab). These therapies target major therapeutic areas such as oncology, ophthalmology, and metabolic disorders, providing affordable alternatives to blockbuster reference biologics. As a central entity in Biocon's integrated 'lab-to-market' strategy, Biosimilars Newco facilitates the distribution of life-saving medicines across more than 120 countries. The company continues to expand its commercial footprint with recent approvals for denosumab biosimilars and ongoing development of advanced-stage assets in immunology and bone health.